UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Investigational new drugs, 2020-04, Vol.38 (2), p.468-477

2020

Volltextzugriff (PDF)

Multicellular model of angiogenesis

AIMS bioengineering, 2022, Vol.9 (1), p.44-60

2022

Volltextzugriff (PDF)

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study

Japanese journal of clinical oncology, 2018-08, Vol.48 (8), p.736-742

2018

Volltextzugriff (PDF)

Modeling and Simulation of Orlistat to Predict Weight Loss and Weight Maintenance in Obesity Patients

DRUG METABOLISM AND PHARMACOKINETICS, 2014, Vol.29 (3), p.278-282

2014

Volltextzugriff (PDF)

Optimization of dosing regimen for MIRCERA® (Epoetin beta pegol) based on pharmacokinetic properties

Drug Delivery System, 2015/03/25, Vol.30(2), pp.139-144

Nakai, Kiyohiko

2015

Volltextzugriff (PDF)

Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment

Clinical pharmacokinetics, 2015-03, Vol.54 (3), p.295-304

2015

Volltextzugriff (PDF)

Erratum to: Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment

Clinical pharmacokinetics, 2015-04, Vol.54 (4), p.455-455

2015

Volltextzugriff (PDF)

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties

European journal of drug metabolism and pharmacokinetics, 2016-04, Vol.41 (2), p.139-147

2016

Volltextzugriff (PDF)

Safety and Tolerability of Obinutuzumab (GA101) with Shorter Duration of Infusion in Japanese Patients with Previously Untreated CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)-Comparison with GAO4915g (GATHER) and BO21005 (GOYA) Studies

Blood, 2016-12, Vol.128 (22), p.5389-5389

2016

Volltextzugriff (PDF)

Effective use of modeling and simulation in designing bioequivalence and comparability studies of large-molecule compounds: the case of erythropoietin

International journal of clinical pharmacology and therapeutics, 2015-06, Vol.53 (6), p.488

2015

Volltextzugriff (PDF)

Studies on the Metabolic Fate of M17055 a Novel Diuretic (4): Species Difference in Metabolic Pathway and Identification of Human CYP Isoform Responsible for the Metabolism of M17055

DRUG METABOLISM AND PHARMACOKINETICS, 2002, Vol.17 (1), p.60-74

2002

Volltextzugriff (PDF)

Abstract CT228: Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT228-CT228

2015

Volltextzugriff (PDF)

Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2540-2540

2015

Volltextzugriff (PDF)

薬物動態学的特性に基づくミルセラ®（エポエチンベータ　ペゴル）の用法・用量の設定

Drug Delivery System, 2015/03/25, Vol.30(2), pp.139-144

中井, 清彦

2015

Volltextzugriff (PDF)

Studies on the Metabolic Fate of M17055, a Novel Diuretic (5): Pharmacokinetics and Pharmacodynamics of Unchanged Drug in Rat and Dog After Intravenous Administration of M17055

Drug metabolism and pharmacokinetics, 2002, Vol.17 (3), p.214-220

2002

Volltextzugriff (PDF)

Analysis of O-Phosphoamino Acids in the Protein Fractions of Mouse Tissue by Gas Chromatography

Bioscience, biotechnology, and biochemistry, 1992, Vol.56 (8), p.1300-1301

1992

Volltextzugriff (PDF)

Studies on the Metabolic Fate of M17055, a Novel Diuretic

DRUG METABOLISM AND PHARMACOKINETICS, 2002, Vol.17 (3), p.214-220

2002

Volltextzugriff (PDF)

Increase of Phosphotyrosine Levels in Mouse Urine and Liver during Liver Regeneration after Partial Hepatectomy

Biochemical and biophysical research communications, 1994-06, Vol.201 (2), p.909-916

1994

Volltextzugriff (PDF)

Analysis of free and bound O-phosphoamino acids in urine by gas chromatography with flame photometric detection

Biomedical chromatography, 1993-07, Vol.7 (4), p.184-188

1993

Volltextzugriff (PDF)

Sensitivity of rCBF to focal lesions

Stroke (1970), 1981-09, Vol.12 (5), p.631-635

1981

Volltextzugriff (PDF)

Identification of O-phosphoamino acids in urine hydrolysate by gas chromatography—mass spectrometry

Journal of chromatography, 1993-05, Vol.615 (1), p.136-141

1993

Volltextzugriff (PDF)

Chronic Subdural Hematoma in Early Infants under Six Months of Age

Neurologia medico-chirurgica, 1973, Vol.13 (1), p.135-135

1973

Volltextzugriff (PDF)

Neuroradiologic Study of the Normal Pressure Hydrocephalus

Neurologia medico-chirurgica, 1972, Vol.12 (1), p.334-334

1972

Volltextzugriff (PDF)

Intracranial human chorionic gonadotropin producing tumors (author's transl)

Neurologia medico-chirurgica, 1976-09, Vol.16 (5 pt 2), p.411-418

1976

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)

Sprache

Englisch
(27)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Multicellular model of angiogenesis

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study

Modeling and Simulation of Orlistat to Predict Weight Loss and Weight Maintenance in Obesity Patients

Optimization of dosing regimen for MIRCERA® (Epoetin beta pegol) based on pharmacokinetic properties

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment

Erratum to: Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties

Safety and Tolerability of Obinutuzumab (GA101) with Shorter Duration of Infusion in Japanese Patients with Previously Untreated CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)-Comparison with GAO4915g (GATHER) and BO21005 (GOYA) Studies

Effective use of modeling and simulation in designing bioequivalence and comparability studies of large-molecule compounds: the case of erythropoietin

Studies on the Metabolic Fate of M17055 a Novel Diuretic (4): Species Difference in Metabolic Pathway and Identification of Human CYP Isoform Responsible for the Metabolism of M17055

Abstract CT228: Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients

Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor

薬物動態学的特性に基づくミルセラ®（エポエチンベータ　ペゴル）の用法・用量の設定

Studies on the Metabolic Fate of M17055, a Novel Diuretic (5): Pharmacokinetics and Pharmacodynamics of Unchanged Drug in Rat and Dog After Intravenous Administration of M17055

Analysis of O-Phosphoamino Acids in the Protein Fractions of Mouse Tissue by Gas Chromatography

Studies on the Metabolic Fate of M17055, a Novel Diuretic

Increase of Phosphotyrosine Levels in Mouse Urine and Liver during Liver Regeneration after Partial Hepatectomy

Analysis of free and bound O-phosphoamino acids in urine by gas chromatography with flame photometric detection

Sensitivity of rCBF to focal lesions

Identification of O-phosphoamino acids in urine hydrolysate by gas chromatography—mass spectrometry

Chronic Subdural Hematoma in Early Infants under Six Months of Age

Neuroradiologic Study of the Normal Pressure Hydrocephalus

Intracranial human chorionic gonadotropin producing tumors (author's transl)

Suchergebnisse filtern